ICG-enhanced TTT effectively treats retinoblastoma

Article

Indocyanine green (ICG) enhanced transpupillary thermotherapy (TTT) in combination with ophthalmic artery chemosurgery can effectively treat retinoblastoma refractory without ocular side effects, claims a study.

Indocyanine green (ICG) enhanced transpupillary thermotherapy (TTT) in combination with ophthalmic artery chemosurgery can effectively treat retinoblastoma refractory without ocular side effects, claims a study.

The single centre, retrospective study, performed by Dr David H Abramson, Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Centre, New York, USA, included 16 eyes of 13 retinoblastoma patients treated with TT and ICG using an indirect ophthalmoscope. The outcome measures were tumour response and electroretinogram.

After treatment significant tumour regression was seen in all eyes. Well-differentiated characteristics were seen in 13 eyes, two eyes had implanting vitreous seeds and one eye was refractory to traditional TT.

All eyes retained ERG function. Meaning ICG-enhanced TTT with ophthalmic artery chemosurgery can treat retinoblastoma, similarly to conventional focal treatments.

The abstract can be viewed in the latest edition of British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.